April 12, 2022

Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates 

 

March 21, 2022

Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine

 

January 24, 2022

Chimeron Bio Expands Footprint in Philadelphia by Joining BioLabs at The Curtis

 

March 10, 2021

Chimeron Bio Appoints Dr. Juan José Daboub, Eminent Expert in International Trade and Business Development and Dr. Wilmot James, Distinguished Global Health Policy Scholar to its Accessible Medicines Advisory Board (AMAB)

 

February 8, 2021

Chimeron Bio Establishes Accessible Medicines Advisory Board (AMAB) and Appoints Mr. Sven Otto Littorin, Former Minister of Employment of Sweden, to Lead It

 

December 7, 2020

Chimeron Bio Appoints CEO of Evox Therapeutics and Former CSO of Moderna, Dr. Antonin de Fougerolles to Its Scientific Advisory Board

 

August 31, 2020

Pennsylvania Awards Philadelphia’s Biotech Chimeron Bio $600,000 for COVID-19 Vaccine Development

 

July 30, 2020

Chimeron Bio’s COVID-19 Vaccine Demonstrates Positive Pre-Clinical Results

 

May 28, 2020

Chimeron Bio and George Mason University’s National Center for Biodefense and Infectious Diseases Partner to Develop a Coronavirus (COVID-19) Vaccine using ChaESAR™ Technology

 

April 16, 2020

Chimeron Bio Appoints Eminent Virologist Dr. Jonathan Smith to its Scientific Advisory Board as it Initiates COVID-19 Vaccine Program

 

April 2, 2020

A Message from the CEO on the COVID-19 Initiative

 

March 17, 2020

Chimeron Bio Launches Vaccine Program for COVID-19

 

February 12, 2020

Chimeron Bio Announces Appointment of Dr. Dominique Gouty to its Scientific Advisory Board

 

October 22, 2019

Chimeron Bio Announces Appointment of Dr. Robert (Bob) Willette to its Scientific Advisory Board

 

September 6, 2019

Chimeron Bio Announces Appointment of Dr. Afshin Safavi to Chairman of the Board